This is a preview of subscription content, log in via an institution to check access.
References
Adelman B, Sandrock A, Panzara MA (2005) Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 353:432–433
Bauer R, Humphries M, Fassler R, Winklmeier A, Craig SE, Bossehoff AK (2006) Regulation of integrin activity by MIA. J Biol Chem 281:11669–11677
Davenpor RJ, Munday JR (2007) Alpha4-integrin antagonism—an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12(13-14):569
http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol-TPME. Accessed 29 April 2009
Kedl RM, Mescher MF (1997) Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumour. J Immunol 159:650–663
Larouche N, Larouche K, Be’liveau A et al (1998) Transcriptional regulation of the alpha 4-integrin subunit gene in the metastatic spread of uveal melanoma. Anticancer Res 18(5a):3539–3547
Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358(6):647–648
Ogawa M, Tsutsui T, Zou JP et al (1997) Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumour sites following administration of interleukin 12. Cancer Res 57:2216–2222
Panzara MA, Bozic C, Sandrock AW (2008) More on melanoma with transdifferentiation. N Engl J Med 359(1):99
Polman CH, O’Connor PW, Havrdova E et al (2006) A randomised placebo- controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 354:899–910
Qian F, Vaux DL, Weissman IL (1994) Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 77(3):335–347
Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923
Stüve O, Marra CM, Bar-Or A et al (2006) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63(10):1383–1387
Ulrich C, Schmook T, Sachse MM et al (2004) Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 30:622–627
Yang Y, Cardarelli PM, Lehnert K et al (1998) LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides. Eur J Immunol 28(3):995–1004
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ismail, A., Kemp, J. & Sharrack, B. Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis. J Neurol 256, 1771–1772 (2009). https://doi.org/10.1007/s00415-009-5200-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-5200-9